Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Suspended 1Completed 1

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Head & Neck 2Gastrointestinal 2Breast 2Tumor-Agnostic 1Thoracic 1Lymphoid 1CNS 1

Conditions

Breast Neoplasms 2Hot Flashes 1Depressive Disorder, Major 1Depression 1

Interventions

Trastuzumab 732Paclitaxel 695Cyclophosphamide 647Docetaxel 560Capecitabine 486Letrozole 437Fulvestrant 400Carboplatin 398Doxorubicin 341Tamoxifen 308Anastrozole 279pembrolizumab 274exemestane 258Epirubicin 251pertuzumab 240Radiotherapy 239palbociclib 224Bevacizumab 222Gemcitabine 215Vinorelbine 197Lapatinib 181130-nm albumin-bound paclitaxel 172Magnetic Resonance Spectroscopy 164Albumin-Bound Paclitaxel 157eribulin 154Surveys and Questionnaires 152Exercise 151Drug Therapy 141Taxes 134Fluorouracil 133

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Escitalopram × Breast × Clear all
NCT04973930 2025-05-13

IPT

New York State Psychiatric Institute

Phase 3 Suspended
20 enrolled
Breast

Breast Neoplasms, Depressive Disorder, Major

NCT00667121 2025-02-14

Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline

Mayo Clinic

Completed
88 enrolled
Breast

Breast Neoplasms, Depression, Hot Flashes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡